Table I.
Mapping of the laboratory tests used for blood donor screening in the period 2010–2013.
| Infection | Tests | N. of countries (n=30) |
|---|---|---|
| HIV | NAT | 22 |
| ID | 7 | |
| ID or MP | 5 | |
| MP | 10 | |
| Anti-HIV | 30 | |
|
| ||
| HCV | NAT | 22 |
| ID | 7 | |
| ID or MP | 5 | |
| MP | 10 | |
| Anti-HCV | 30 | |
|
| ||
| HBV | NAT | 22 |
| ID | 7 | |
| ID or MP | 5 | |
| MP | 10 | |
| HBsAg | 30 | |
| Anti-HBc | 18 | |
| Partial* anti-HBc | 6 | |
|
| ||
| Syphilis | Anti-lues | 28 |
|
| ||
| HTLV I/II | Anti-HTLV | 12 |
| Partial* | 6 | |
|
| ||
| Other: | ||
| CMV | Anti-CMV | 14 |
| Partial | 11 | |
| Malaria | Anti-malaria (partial*) | 7 |
| Chagas | Anti-Trypanosoma cruzi (partial*) | 6 |
| Parvovirus B19 | Anti-ParvoB19 (partial*) | 1 |
*
Partial screening means selective screening of newly registered donors only or when not implemented in the whole country or implemented during the observed period of this study. HIV: human immunodeficiency virus; NAT: nucleic-acid amplification testing; ID: individual donation testing; MP: mini-pool of 6, 24 or 96 samples testing; HCV: hepatitis C virus; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBc: hepatitis B core antigen; HLTV: human T-lymphotropic virus; CMV: cytomegalovirus.